910 related articles for article (PubMed ID: 27863197)
1. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O
J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197
[TBL] [Abstract][Full Text] [Related]
2. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.
Herbst RS; Baas P; Perez-Gracia JL; Felip E; Kim DW; Han JY; Molina JR; Kim JH; Dubos Arvis C; Ahn MJ; Majem M; Fidler MJ; Surmont V; de Castro G; Garrido M; Shentu Y; Emancipator K; Samkari A; Jensen EH; Lubiniecki GM; Garon EB
Ann Oncol; 2019 Feb; 30(2):281-289. PubMed ID: 30657853
[TBL] [Abstract][Full Text] [Related]
3. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041).
Yamazaki N; Takenouchi T; Fujimoto M; Ihn H; Uchi H; Inozume T; Kiyohara Y; Uhara H; Nakagawa K; Furukawa H; Wada H; Noguchi K; Shimamoto T; Yokota K
Cancer Chemother Pharmacol; 2017 Apr; 79(4):651-660. PubMed ID: 28283736
[TBL] [Abstract][Full Text] [Related]
4. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
Keung EZ; Burgess M; Salazar R; Parra ER; Rodrigues-Canales J; Bolejack V; Van Tine BA; Schuetze SM; Attia S; Riedel RF; Hu J; Okuno SH; Priebat DA; Movva S; Davis LE; Reed DR; Reuben A; Roland CL; Reinke D; Lazar AJ; Wang WL; Wargo JA; Tawbi HA
Clin Cancer Res; 2020 Mar; 26(6):1258-1266. PubMed ID: 31900276
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
Olson DJ; Eroglu Z; Brockstein B; Poklepovic AS; Bajaj M; Babu S; Hallmeyer S; Velasco M; Lutzky J; Higgs E; Bao R; Carll TC; Labadie B; Krausz T; Zha Y; Karrison T; Sondak VK; Gajewski TF; Khushalani NI; Luke JJ
J Clin Oncol; 2021 Aug; 39(24):2647-2655. PubMed ID: 33945288
[TBL] [Abstract][Full Text] [Related]
6. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Hamid O; Robert C; Daud A; Hodi FS; Hwu WJ; Kefford R; Wolchok JD; Hersey P; Joseph RW; Weber JS; Dronca R; Gangadhar TC; Patnaik A; Zarour H; Joshua AM; Gergich K; Elassaiss-Schaap J; Algazi A; Mateus C; Boasberg P; Tumeh PC; Chmielowski B; Ebbinghaus SW; Li XN; Kang SP; Ribas A
N Engl J Med; 2013 Jul; 369(2):134-44. PubMed ID: 23724846
[TBL] [Abstract][Full Text] [Related]
7. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
[TBL] [Abstract][Full Text] [Related]
8. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
Armand P; Shipp MA; Ribrag V; Michot JM; Zinzani PL; Kuruvilla J; Snyder ES; Ricart AD; Balakumaran A; Rose S; Moskowitz CH
J Clin Oncol; 2016 Nov; 34(31):3733-3739. PubMed ID: 27354476
[TBL] [Abstract][Full Text] [Related]
9. PD-1 and PD-L1 antibodies for melanoma.
Tsai KK; Zarzoso I; Daud AI
Hum Vaccin Immunother; 2014; 10(11):3111-6. PubMed ID: 25625924
[TBL] [Abstract][Full Text] [Related]
10. Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma.
Tarhini AA; Zahoor H; Yearley JH; Gibson C; Rahman Z; Dubner R; Rao UN; Sander C; Kirkwood JM
J Transl Med; 2015 Sep; 13():319. PubMed ID: 26419843
[TBL] [Abstract][Full Text] [Related]
11. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
Nghiem PT; Bhatia S; Lipson EJ; Kudchadkar RR; Miller NJ; Annamalai L; Berry S; Chartash EK; Daud A; Fling SP; Friedlander PA; Kluger HM; Kohrt HE; Lundgren L; Margolin K; Mitchell A; Olencki T; Pardoll DM; Reddy SA; Shantha EM; Sharfman WH; Sharon E; Shemanski LR; Shinohara MM; Sunshine JC; Taube JM; Thompson JA; Townson SM; Yearley JH; Topalian SL; Cheever MA
N Engl J Med; 2016 Jun; 374(26):2542-52. PubMed ID: 27093365
[TBL] [Abstract][Full Text] [Related]
12. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.
Chen G; Huang AC; Zhang W; Zhang G; Wu M; Xu W; Yu Z; Yang J; Wang B; Sun H; Xia H; Man Q; Zhong W; Antelo LF; Wu B; Xiong X; Liu X; Guan L; Li T; Liu S; Yang R; Lu Y; Dong L; McGettigan S; Somasundaram R; Radhakrishnan R; Mills G; Lu Y; Kim J; Chen YH; Dong H; Zhao Y; Karakousis GC; Mitchell TC; Schuchter LM; Herlyn M; Wherry EJ; Xu X; Guo W
Nature; 2018 Aug; 560(7718):382-386. PubMed ID: 30089911
[TBL] [Abstract][Full Text] [Related]
13. Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.
Faiena I; Astrow SH; Elashoff DA; Jain R; Bot A; Chamie K; Belldegrun AS; Pantuck AJ; Drakaki A
Cancer Immunol Immunother; 2019 May; 68(5):743-751. PubMed ID: 30790015
[TBL] [Abstract][Full Text] [Related]
14. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM.
Placke JM; Kimmig M; Griewank K; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Welzel J; Engel DR; Kreft S; Sucker A; Lodde G; Krefting F; Stoffels I; Klode J; Roesch A; Zimmer L; Livingstone E; Hadaschik E; Becker JC; Weichenthal M; Tasdogan A; Schadendorf D; Ugurel S
EBioMedicine; 2023 Oct; 96():104774. PubMed ID: 37660535
[TBL] [Abstract][Full Text] [Related]
15. Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients.
Khoja L; Kibiro M; Metser U; Gedye C; Hogg D; Butler MO; Atenafu EG; Joshua AM
Br J Cancer; 2016 Nov; 115(10):1186-1192. PubMed ID: 27701388
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study.
Khattak MA; Reid A; Freeman J; Pereira M; McEvoy A; Lo J; Frank MH; Meniawy T; Didan A; Spencer I; Amanuel B; Millward M; Ziman M; Gray E
Oncologist; 2020 Mar; 25(3):e520-e527. PubMed ID: 32162809
[TBL] [Abstract][Full Text] [Related]
17. PD-1 Blockade in Anaplastic Thyroid Carcinoma.
Capdevila J; Wirth LJ; Ernst T; Ponce Aix S; Lin CC; Ramlau R; Butler MO; Delord JP; Gelderblom H; Ascierto PA; Fasolo A; Führer D; Hütter-Krönke ML; Forde PM; Wrona A; Santoro A; Sadow PM; Szpakowski S; Wu H; Bostel G; Faris J; Cameron S; Varga A; Taylor M
J Clin Oncol; 2020 Aug; 38(23):2620-2627. PubMed ID: 32364844
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma.
Marmarelis ME; Wang X; Roshkovan L; Grady CB; Miura JT; Ginsberg MS; Ciunci CA; Egger J; Walker S; Cercek A; Foote MB; Litzky LA; Nash G; Haas AR; Karakousis GC; Cengel KA; Katz SI; Zauderer MG; Langer CJ; Offin M
JAMA Netw Open; 2023 Mar; 6(3):e232526. PubMed ID: 36897589
[TBL] [Abstract][Full Text] [Related]
19. Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119.
Cortes J; Winer EP; Lipatov O; Im SA; Gonçalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Hund S; Kulangara K; Karantza V; Mejia JA; Ma J; Jelinic P; Huang L; Pruitt SK; Emancipator K
J Pathol Clin Res; 2024 May; 10(3):e12371. PubMed ID: 38627977
[TBL] [Abstract][Full Text] [Related]
20. Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor.
Suteau V; Collin A; Menei P; Rodien P; Rousselet MC; Briet C
Cancer Immunol Immunother; 2020 Oct; 69(10):2053-2061. PubMed ID: 32445029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
